Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study is for patients who have stomach cancer or cancer of the lower part of the
esophagus that has spread to other organs. There are many different chemotherapy treatments
for this type of cancer. At the present time, there is no general agreement on the way to
choose the most beneficial therapy for an individual patient. Patients with different genetic
backgrounds may respond differently to the same chemotherapy treatments. In this study the
investigators will use a certain genetic difference in an important gene (thymidylate
synthase or TS gene) to see whether treating patients who have a particular type of that gene
will respond better to a standard chemotherapy regimen. The investigators are hoping that by
treating patients according to their genes, that they may respond to treatment of their
cancer better and it will help the investigators choose cancer treatments better in the
future.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Collaborators:
National Cancer Institute (NCI) University of Alabama at Birmingham University of North Carolina Washington University School of Medicine